<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826212</url>
  </required_header>
  <id_info>
    <org_study_id>NOVA-BF-SBG</org_study_id>
    <nct_id>NCT03826212</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Soybean Germ Extract on Decrease of Body Fat</brief_title>
  <official_title>A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Soybean Germ Extract on Decrease of Body Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to investigate the effects of daily supplementation of Soybean germ
      extract on decrease of body fat
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. 80
      subjects were randomly divided into Soybean germ extract 1,600 mg or placebo group. The
      investigators measured Body Fat Mass, Percent Body Fat, Fat Free Mass, weight, and body mass
      index, etc.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of body fat mass</measure>
    <time_frame>Baseline and 12 week</time_frame>
    <description>Body fat mass was measured in study baseline and 12 week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of percent body fat</measure>
    <time_frame>Baseline and 12 week</time_frame>
    <description>Measurement is made using dual energy X-ray absorptiometry (DEXA / Hologic Discovery, USA). Left arm, right arm, left leg, right leg, trunk, total will be report percent body fat in %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of fat free mass</measure>
    <time_frame>Baseline and 12 week</time_frame>
    <description>Measurement is made using dual energy X-ray absorptiometry (DEXA / Hologic Discovery, USA). Left arm, right arm, left leg, right leg, trunk, total will be report fat free mass in g.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Anthropometric indicate: body weight</measure>
    <time_frame>Screening, baseline and 12 week</time_frame>
    <description>Anthropometric indices were measured in study screening, baseline and 12 week. Body weight in kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Anthropometric indicate: body mass index</measure>
    <time_frame>Screening, baseline and 12 week</time_frame>
    <description>Anthropometric indices were measured in study screening, baseline and 12 week. Weight/height^2 will be report body mass index in kg/m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Anthropometric indices: waist circumference, hip circumference</measure>
    <time_frame>Screening, baseline and 12 week</time_frame>
    <description>Anthropometric indices were measured in study screening, baseline and 12 week. Waist circumference, hip circumference in cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Anthropometric indicate: waist -hip circumference ratio</measure>
    <time_frame>Screening, baseline and 12 week</time_frame>
    <description>Anthropometric indices were measured in study screening, baseline and 12 week. Waist circumference/hip circumference will be report waist -hip circumference ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of lipid metabolism indicators: Total cholesterol, Triglyceride, LDL-cholesterol, HDL-cholesterol</measure>
    <time_frame>Baseline and 12 week</time_frame>
    <description>Lipid metabolism indicators(mg/dL) were measured in study baseline and 12 week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of obesity-related hormones indicators: Adiponectin, Leptin</measure>
    <time_frame>Baseline and 12 week</time_frame>
    <description>obesity-related hormones indicators were measured in study baseline and 12 week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of energy expenditure Indicators: Uncoupling protein-1(UCP-1), Peroxisome proliferator-activated receptor gamma coactivator-1 α(PGC-1 α)</measure>
    <time_frame>Baseline and 12 week</time_frame>
    <description>energy expenditure Indicators were measured in study baseline and 12 week</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Soybean Germ Extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soybean Germ Extract 1,600 mg/day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1,600 mg/day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soybean Germ Extract</intervention_name>
    <description>Soybean Germ Extract 1,600 mg/day for 12 weeks.</description>
    <arm_group_label>Soybean Germ Extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1,600 mg/day for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 19 and 65 years

          -  BMI 25~29.9 kg/m^2

          -  After fully hearing and fully understanding this clinical trials, those who agree to
             voluntarily decide to participate and to comply with the notice

        Exclusion Criteria:

          -  Those who lost more than 10% of their weight within 3 months before the screening

          -  Those who take a product(body fat improvement health functional foods, birth control
             pills, steroids, female hormone) that affects your weight within 4 weeks prior to the
             screening

          -  Those with clinically significant severe cardiovascular, endocrine, immune,
             respiratory, liver, biliary, renal and urinary tract, neuropsychiatry,
             musculoskeletal, inflammatory and hematologic and gastrointestinal disorders

          -  Diabetic patients taking oral hypoglycemic agents or insulin (based on screening
             subjects)

          -  A person with a history of clinically significant hypersensitivity to soybeans

          -  Those who have received antipsychotic medication within 2 months before screening

          -  Anyone with substance abuse or suspicion

          -  Those who participated in other clinical trials within 3 months before screening

          -  Systolic Blood Pressure(SBP) 180 mmHg, Diastolic Blood Pressure(DBP) 110 mmHg or more

          -  Menopausal woman

          -  Laboratory test by show the following results

               -  Aspartate Transaminase(AST), Alanine Transaminase(ALT) &gt; Reference range 3 times
                  upper limit

               -  Serum Creatinine &gt; 2.0 mg/dL

          -  Pregnancy or breast feeding

          -  Those who doesn't accept the implementation of appropriate contraception of a
             childbearing woman

          -  Principal Investigator judged inappropriate for participation in study because of
             Laboratory test result, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Soo Wan Chae, Ph.D., M.D.</last_name>
    <phone>82-63-259-3040</phone>
    <email>soowan@jbnu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Center for Functional Foods Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo-Wan Chae, MD., PhD</last_name>
      <phone>82-63-259-3040</phone>
      <email>swchae@jbctc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Trial Center for Functional Foods</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

